

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

6 - 12 July 2026



US Tariffs on Chinese Chemicals Shift to New 12.5% Section 301 Rate

Following recent US-China trade talks, both nations agreed to reciprocal tariff reductions exceeding \$30 billion, benefiting basic chemicals. However, a complex shift occurred on July 24, 2026. As the US 10% temporary global surcharge expires, a new tiered Section 301 tariff will immediately take effect, placing mainland Chinese chemical exports into the highest 12.5% tax bracket. **(ChemNet Chemical Headlines)**

Six Chinese Departments Launch Crackdown on High-Risk Chemical Violations

Six Chinese government departments, including the Ministry of Emergency Management and Public Security, have launched a nationwide crackdown targeting the high-risk chemical and hazardous materials sectors. The campaign strictly penalizes unlicensed production, unauthorized operations, and safety falsifications. Authorities deploy digital monitoring tools, enforce criminal liability for major accidents to eliminate safety risks. **(ChemNet Chemical Headlines)**

Thailand Initiates Anti-dumping Investigation into Polyvinyl Chloride from China

On June 29, 2026, the Department of Foreign Trade of the Thai Ministry of Commerce issued a notice stating that, in response to applications submitted by Thai domestic companies, it has initiated an anti-dumping investigation into polyvinyl chloride originating from mainland China and Taiwan. This case involves products under Thai Customs codes 3904.10.10, 3904.10.91, 3904.10.92, and 3904.10.99. **(Thai Government Gazette)**

China's First Homegrown RSV (Respiratory Syncytial Virus) Vaccine Approved For Older Adults

China has granted marketing authorization to its first domestically developed respiratory syncytial virus vaccine for adults aged 60 and above. The recombinant protein vaccine demonstrated 78.6% efficacy in preventing symptomatic RSV infection in Phase III trials. This approval reduces reliance on imported vaccines and strengthens domestic preparedness for seasonal respiratory outbreaks. **(National Medical Products Administration)**

Breakthrough Approval For China's First Bispecific Antibody In Hematology

China has approved its first indigenous CD20xCD3 bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The novel immunotherapy showed an overall response rate of 68.2% and a complete remission rate of 51.4% in pivotal studies. This milestone accelerates the domestic shift toward innovative, multi-target biological drugs in oncology. **(Center for Drug Evaluation)**